Prevention of rebleeding from oesophageal-gastric varices

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 4, 2001, Pages 343-348

  Rossle M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Evidence based medicine; Quality of life; Secondary prophylaxis; Variceal rebleeding

Indexed keywords

ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; EVIDENCE BASED MEDICINE; HUMAN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME;

ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RECURRENCE; RETREATMENT; SCLEROTHERAPY; TREATMENT FAILURE;

EID: 0035045789     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200104000-00007     Document Type: Review

References (48)

1. Portal Hypertension II
2. Portal hypertension and variceal bleeding: An AASLD single topic symposium
3. Treatment of portal hypertension: A meta-analytic review
4. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis
5. Performance of an intrahepatic portacaval shunt using a catheter technique - A case report
6. Transjugular intrahepatic portocaval stent-shunt: Preliminary clinical results
7. Creation of transjugular intrahepatic portosystemic shunts with the Wallstent endoprosthesis: Results in 100 patients
8. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding
9. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage
10. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding
11. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial
12. Endoscopic sclerotherapy compared with percutaneous transjugular intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal hemorrhage
13. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding
14. A randomized trial comparing transjugular intrahepatic portosystemic stentshunt with variceal band ligation in the prevention of rebleeding from esophageal varices
15. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial
16. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal rebleeding after recent variceal hemorrhage
17. TIPS versus sclerotherapy plus propranolol in the prevention of variceal rebleeding: Preliminary results of a multicenter randomized trial
18. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: A comparative randomized clinical trial (interim analysis)
19. Transjugular intrahepatic portosystemic stent-shunt (TIPS) vs endoscopic banding in the prevention of variceal rebleeding: Final results of a randomized study
20. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis
21. TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials
22. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for prevention of recurrent esophageal variceal bleeding
23. Effect of transjugular intrahepatic portosystemic shunt on quality of life
24. A prospective evaluation of changes in neuropsychological and liver function tests following transjugular intrahepatic portosystemic stent-shunt
25. A prospective trial of transjugular intrahepatic portosystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices
26. A comparative study of emergency transjugular intrahepatic porto-systemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage
27. N-butyl-2-cyanoacrylate (Histoacryl) plus sclerotherapy versus sclerotherapy alone in the treatment of bleeding esophageal varices: A randomized prospective study
28. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study
29. 1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis
30. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: The good, the bad, the ugly
31. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin, and nitric oxide
32. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin-1 and nitric oxide in the regulation of the sinusoidal tonus
33. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance
34. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells
35. Effect of intraportal BQ-123, an endothelin receptor-A inhibitor, on portal pressure in patients receiving a transjugular intrahepatic portosystemic shunt: Comparison with propranolol and giycylpressin
36. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): State of the art
37. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: A randomized study comparing trapidil plus ticlopidine with heparin treatment
38. Improved patency of transjugular intrahepatic portosystemic shunts in humans: Creation and revision with PTFE stent-grafts
39. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multi-center study
40. Duplex sonographic evaluation before and after TIPS: Monitoring of shunt function
41. Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings
42. Duplex sonography and TIPS
43. The inaccuracy of duplex ultrasonography in predicting patency of transjugular intrahepatic portosystemic shunt
44. Portal pressure, presence of gastroesophageal varices, and variceal bleeding
45. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis
46. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension
47. Clinical versus haemodynamic response to drugs in portal hypertension
48. How much pressure reduction is necessary to prevent rebleeding?